Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.BMC cardiovascular disorders · 2017
   Trial
2. Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices.Pulmonary circulation · 2025
   Article
3. Shuttling toward Improved Clinic-based Assessment of Exercise Capacity in Pulmonary Arterial Hypertension.Annals of the American Thoracic Society · 2021
   Article
4. The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.Current hypertension reports · 2019
   Review
5. A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States.Journal of managed care & specialty pharmacy · 2017
   Review
6. A Contemporary Approach to Pulmonary Arterial Hypertension.Current atherosclerosis reports · 2016
   Review
7. Are hemodynamics surrogate end points in pulmonary arterial hypertension?Circulation · 2014
   Article
8. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?Drug design, development and therapy · 2014
   Review
9. The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.Pulmonary circulation
   Article

Corrections and comments

• Comment on
  Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as